Cardiff Oncology Inc. Stock
Cardiff Oncology Inc. Stock
Pros and Cons of Cardiff Oncology Inc. in the next few years
Pros
Cons
Performance of Cardiff Oncology Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cardiff Oncology Inc. | -3.130% | 4.487% | -17.343% | 159.554% | 209.650% | -48.418% | 16.429% |
| Thermogenesis Holdings Inc. | 1.640% | 0.000% | 0.000% | -68.844% | 8.772% | -99.379% | -99.420% |
| NanoVibronix Inc. | -0.730% | -2.857% | -17.073% | -77.632% | -35.849% | - | - |
| Sintx Technologies Inc. | -17.300% | 18.056% | -6.593% | -97.128% | -88.062% | -99.966% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financial statements of Cardiff Oncology (TROV), a player in the dynamic Healthcare Equipment & Supplies industry, reveals a singular focus on research and innovation as observed from substantial investments in research and development. However, the financial performance in recent years has underscored considerable challenges. Despite a keen dedication to advancing oncology treatments, the company's financials reflect its pre-revenue stage and the typical high-burn nature of clinical-stage biotech companies.
Starting with the balance sheets, the total assets of the company have shown variability with an observed peak in 2021. As of December 2022, Cardiff Oncology reported total assets of approximately $116.2 million. A closer look at the components of assets reveals a strong liquidity position, evidenced by sizable cash reserves of $16.3 million and significant short-term investments amounting to $88.9 million. The net working capital of over $103 million and a net invested capital of $106.3 million suggest that Cardiff is maintaining a robust buffer to support its operations.
Stockholder equity remains positive, amounting to $106.34 million as of the end of 2022, implying a decent financial buffer for stakeholders. The company also doesn’t seem to have over-leveraged with its retained earnings standing at a deficit of approximately $298.1 million, possibly an accumulation of years of focused R&D spend without proportional revenue generation.
